13F reference period
Q2 2026
Security Snapshot
CASI Pharmaceuticals, Inc. - Ordinary Shares (CASIF) Institutional Ownership
CUSIP: G1933S101
13F Institutional Holders and Ownership History from Q4 2022 to Q3 2026
Institutions Reporting
1
Shares (Excl. Options)
100
Price
$0.17
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares
- Symbol
- CASIF on OTC
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 100
- Total 13F value
- $17
- Portfolio coverage rank
- 0%
- Share change
- -128
- Value change
- -$8
- Number of holders
- 1
- Shares outstanding
- 40,791,726
- SEC-reported price per share
- $0.11
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- CASIF - CASI Pharmaceuticals, Inc. - Ordinary Shares is tracked under CUSIP G1933S101.
- 1 institution reported positions in Q2 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 1 to 1 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $25 to $17.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 1 institution filings for Q2 2026.
Security key
G1933S101
13F reference period
Q2 2026
13F holders
1
13D/G owners
7
CIK / CUSIP context first
Open Q2 2026 holders
CASIF full holder history
CASI Pharmaceuticals, Inc. SEC filings
CASI Pharmaceuticals, Inc. company facts
CASI Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G1933S101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
CASIF
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| He Wei-Wu | 59% | +11% | $3,118,120 | +$650,000 | 23,985,535 | +26% | WEI-WU HE, Ph.D. | 18 May 2026 |
| Panacea Innovation Ltd | 22% | +13% | $4,698,042 | +$999,856 | 4,651,527 | +27% | James Huang | 16 Dec 2025 |
| Chen Zhenfeng M | 11% | $4,150,370 | 2,255,636 | Chen Zhenfeng | 30 Sep 2025 | |||
| Huang James | 14% | $3,177,509 | 2,161,571 | James Huang | 30 Jun 2025 | |||
| Venrock Healthcare Capital Partners III, L.P. | 9.2% | $2,066,749 | 1,987,259 | Venrock Healthcare Capital Partners III, L.P. | 31 Dec 2025 | |||
| SPARKLE BYTE LTD | 5% | $775,088 | 1,019,852 | SPARKLE BYTE LTD | 30 Sep 2025 | |||
| Ho Chi Sing | 4.8% | -27% | $754,405 | 992,638 | 0% | Zhou Quan | 30 Sep 2025 |
As of 30 Jun 2026, 1 institutional investors reported holding 100 shares of CASI Pharmaceuticals, Inc. - Ordinary Shares (CASIF). This represents 0% of the company’s total 40,791,726 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
16
Headline period
Q2 2026
Rows shown
1-16 of 16
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 100 | $11 | $0.11 | 1 | |
| 2026 Q2 | 100 | $17 | -$8 | $0.17 | 1 |
| 2026 Q1 | 228 | $25 | -$1,063,614 | $0.11 | 1 |
| 2025 Q4 | 1,251,879 | $1,063,851 | -$2,036,507 | $0.85 | 16 |
| 2025 Q3 | 2,606,843 | $4,327,257 | +$649,422 | $1.66 | 21 |
| 2025 Q2 | 2,245,168 | $2,648,852 | -$589,075 | $1.18 | 23 |
| 2025 Q1 | 2,744,278 | $5,927,688 | +$186,001 | $2.16 | 22 |
| 2024 Q4 | 2,658,168 | $7,523,090 | -$53,802 | $2.83 | 22 |
| 2024 Q3 | 1,322,529 | $8,138,853 | +$5,984,886 | $6.16 | 20 |
| 2024 Q2 | 352,170 | $1,936,256 | +$552,357 | $5.50 | 23 |
| 2024 Q1 | 252,002 | $909,576 | -$261,433 | $3.61 | 20 |
| 2023 Q4 | 275,894 | $1,981,066 | -$338,820 | $7.16 | 17 |
| 2023 Q3 | 344,608 | $882,628 | -$268,771 | $2.56 | 18 |
| 2023 Q2 | 449,838 | $1,124,376 | -$1,180,810 | $2.50 | 18 |
| 2023 Q1 | 929,752 | $2,152,582 | +$2,152,350 | $2.32 | 19 |
| 2022 Q4 | 100 | $179 | +$179 | $1.79 | 1 |